Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Immunotherapy Drugs Market Size to Hit US$ 3.01 Billion By 2030 | Prediction by Growth Plus Reports

This image opens in the lightbox

News provided by

Growth Plus Reports

29 Jul, 2022, 13:00 GMT

Share this article

Share toX

Share this article

Share toX

NEW YORK, July 29, 2022 /PRNewswire/ -- The global immunotherapy drugs market is expected to clock ~US$ 3.01 billion by 2030 owing to the rising prevalence of different types of cancers & infectious diseases coupled with the strong product pipeline.

Download Sample Pages Of this report - https://growthplusreports.com/inquiry/request-sample/immunotherapy-drugs-market/7740

Market Driver

Impending global risk of new infectious and chronic diseases majorly drive the global immunotherapy drugs market. The ongoing pandemic of COVID-19 caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has affected almost every country worldwide, and resulted in severe outcomes, across all countries.

The first case of COVID-19 was found in December 2019 and by the end of December 2020, the count surged to more than 90.3 million globally. SARS-CoV-2 monoclonal antibodies have shown the potential benefits in animal model for both prevention and treatment of infection.

Therefore, various government bodies, numerous organizations, and the prominent players across the globe are implementing several strategies to fast-track the development of immunotherapy for treatment & prevention of COVID-19. For instance, in May 2021, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the investigational monoclonal antibody therapy sotrovimab for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients who are at great risk for development to severe Covid-19, comprising hospitalization or death.

The global immunotherapy drugs market has been analyzed from four different perspectives–type, application, end user, and region.

Excerpts from 'By Type Segmentation'

Based on type, the global immunotherapy drugs market has been segmented into:

  • Monoclonal Antibodies
  • Vaccines
  • Interferons & Interleukins
  • Checkpoint Inhibitors
  • Others

The monoclonal antibodies segment dominated the market with largest share in 2020. Monoclonal antibodies are laboratory made antibodies that boost the body's natural antibodies or act as antibodies themselves. These antibodies trigger a targeted response by the body to protect it against an attack from a foreign antigen. Monoclonal antibodies are widely used in oncology to recognize tumor cells and to slow or stop their growth. Furthermore, in past few years, monoclonal antibodies have also found application in the treatment of infectious diseases. More recently, monoclonal antibodies are being actively researched and are given emergency use authorizations in order to battle the COVID-19 pandemic. This factor is further expected to increase the growth of the market.

Get a Sample Copy of the prefilled syringes Market Report 2022

Excerpts from 'By Region Segmentation'

Based on region, the global immunotherapy drugs market has been segmented into

  • North America
  • Europe
  • Asia Pacific
  • Rest of the World

North America dominated the global immunotherapy drugs market in 2021, followed by Asia Pacific. The large share of North America in the global market can largely be attributed to the rising prevalence of different types of cancers and infectious diseases in the region, the presence of prominent players, with the large number of drugs present in the pipeline, favorable reimbursement policies, and the growing funding by public & private organizations for the development of immunotherapies.

Asia Pacific is expected to see significant growth in the immunotherapy drugs market, because of the rising costs of developing healthcare infrastructure. Furthermore, the region's large patient pool and rising cancer cases are expected to drive the growth of the immunotherapy drugs market in the coming years.  Advanced immunotherapy drugs have been introduced in China and Japan as these countries are conducting numerous clinical trials and receiving FDA approvals for new drug molecules and combination therapies.

Excerpts from 'Competitive Landscape'

The prominent players operating in the global immunotherapy drugs market are:

  • Merck & Co., Inc
  • Novartis AG
  • Pfizer Inc
  • Bristol-Myers Squibb Company
  • Johnson & Johnson Service, Inc
  • Bayer AG
  • GlaxoSmithKline plc
  • F. Hoffmann-La Roche Ltd
  • AstraZeneca plc
  • Amgen Inc
  • Among others

Immunotherapy Drugs Market Segmentation:

By Type Outlook

  • Monoclonal Antibodies
  • Vaccines
  • Interferons & Interleukins
  • Checkpoint Inhibitors

By Application Outlook

  • Cancer
  • Infectious Diseases
  • Autoimmune & Inflammatory Diseases

By End User

  • Hospitals
  • Specialty Centers

VALUE PROPOSITIONS RELATED TO THE REPORT:

  • Powered with Complimentary Analyst Hours and Expert Interviews with Each Report
  • Comprehensive quantitative and qualitative insights at segment and sub-segment level
  • Covid 19 impact trends and perspective
  • Granular insights at global/regional/country level
  • Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment
  • Blanket coverage on competitive landscape
  • Winning imperatives
  • Exhaustive coverage on 'Strategic Developments' registered by leading players of the market

CUSTOMIZATION OPTIONS:

  • Distributor Landscape Assessment
  • Pricing Intelligence
  • Customer Base Assessment
  • Investment & Initiatives Analysis
  • 'Business Profile' of Key Players

Purchase this Report (Price 5950 USD for a Single-User License) –  
https://growthplusreports.com/checkout_token=IAiX8QhvTYJZLEQFoX5mSLyViM8zjkMsS3IkE55w&report_id=7740&license=Single

Check out more healthcare industry related studies published by Growth Plus Reports:

Hydroxychloroquine Market by Disease Indication (Malaria, Systemic Lupus Erythematous, and Rheumatoid Arthritis), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Stores)–Global Outlook & Forecast 2021-2031

Acquired Hemophilia Treatment Market by Type (Hemophilia A, Hemophilia B, and Hemophilia C), by Therapy (Gene Therapy, Immune Tolerance Induction Therapy, Replacement Therapy, and Others), by Treatment (On-Demand and Prophylaxis), and by End-User (Hospitals and Clinics) – Global Outlook & Forecast 2022-2030

Diet Pills Market by Product Type (Over the Counter and Prescription), by Application (Fat Blocking and Appetite Suppression), by Distribution Channel (Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies) - Global Outlook & Forecast 2022-2030

Softgel Capsules Market by Type (Gelatin Capsules, Non-animal Capsules), by Application (Health & Dietary Supplements, Prescribed Medicines), by Manufacturer (Nutraceuticals, Pharmaceuticals, Cosmeceuticals) - Global Outlook & Forecast 2022-2030

Alzheimer's Drugs Market by Drug Type [NMDA Receptor Antagonists and Cholinesterase Inhibitors], Distribution Channel [Hospital Pharmacy, Retail Pharmacy and Online Pharmacy] – Global Outlook & Forecast 2021-2031

About Us:

Growth+Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).

Growth+ portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.

We were awarded by the prestigious CEO Magazine as "Most Innovative Healthcare Market Research Company in 2020.

Contact:
Manan Sethi
Director, Market Insights
Email: enquire@growthplusreports.com
Phone no: +91 96545 76783
Web: https://growthplusreports.com/ 
Follow Us: LinkedIn | Twitter

Logo: https://mma.prnewswire.com/media/1671244/Growth_Plus_Reports_Logo.jpg

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.